Tesamorelin
Also known as: Egrifta, TH9507
Overview
A synthetic growth hormone-releasing hormone (GHRH) analog that has been FDA-approved for reducing excess abdominal fat in HIV patients with lipodystrophy. It stimulates the pituitary gland to produce and release growth hormone.
Benefits
- ✓reduction in visceral adipose tissue
- ✓body composition improvement
- ✓metabolic health support
Potential Side Effects
- •injection site reactions
- •joint pain
- •muscle pain
- •peripheral edema
- •carpal tunnel symptoms
Who Should Avoid
- ⚠pregnancy or breastfeeding
- ⚠active malignancy or history of cancer
- ⚠critical illness or post-surgery recovery
- ⚠diabetic retinopathy
- ⚠hypersensitivity to tesamorelin or mannitol
Interactions & Precautions
May affect glucose metabolism and insulin sensitivity. Discuss with clinician if taking diabetes medications, corticosteroids, or other hormonal therapies.
Dosing Information from Literature
FDA-approved dosing for lipodystrophy is 2 mg once daily via subcutaneous injection. Clinical studies have primarily used this standardized dose.
This is descriptive information only. Always consult a licensed healthcare provider for dosing guidance.
Storage
Store unreconstituted vials refrigerated at 2-8°C (36-46°F). After reconstitution, use immediately or store refrigerated for up to 3 hours. Protect from light.